This year’s summer intern class brought fresh perspectives across translational medicine, public affairs, communications, biostatics, healthcare compliance, and more. Thank you for your valuable contributions to Servier this summer!
About us
Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us
- Website
-
https://www.servier.us/
External link for Servier Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Boston , MA
- Type
- Nonprofit
Locations
-
Primary
200 Pier Four Boulevard
Boston , MA 02210, US
Employees at Servier Pharmaceuticals
Updates
-
A glioma diagnosis may come with questions about what to expect. Our team developed My Glioma Guide to help answer some initial questions and provide resources along the way. Take a look: https://ow.ly/2PQ150SWln4
-
Stefan Gross, our Senior Director and Head of Biochemistry, shares the significance of achieving such a major milestone for people living with IDH-mutant glioma. Learn more: https://ow.ly/AoGh50SWVv2
servier.us
-
The resilience of patients and the dedication of the brain cancer community drive everything we do. Learn more about the first targeted therapy FDA approved for patients living with Grade 2 IDH-mutant glioma here: https://ow.ly/lVMB50SWXq5
servier.us
-
A glioma diagnosis is devastating for patients and their families. Their stories of strength and perseverance drive everything we do. Learn more about our commitment to advancing care for patients with IDH-mutant glioma: https://ow.ly/67K450SSYkv
servier.us
-
We are inspired by the fortitude of the brain cancer community and are humbled by their steadfast commitment to supporting patients and their families navigating an IDH-mutant glioma diagnosis. Learn more about the first FDA-approved targeted therapy for Grade 2 IDH-mutant glioma here: https://ow.ly/WJiA50SSwiE
servier.us
-
The FDA approval of the first targeted therapy for Grade 2 IDH-mutant glioma reinforces our commitment to delivering transformative new treatment options to patients in need. Learn more: https://ow.ly/3nX850SRERY
servier.us
-
#BreakingNews We are thrilled to announce that today, the U.S. FDA has approved the first targeted therapy for Grade 2 IDH-mutant glioma. This is the first significant treatment breakthrough for this relentless condition in nearly 25 years. Thank you to the dedicated study participants, researchers, and clinical investigators who made this achievement possible. Learn more about this approval and Servier’s mission to bring transformative new therapies to patients: https://ow.ly/k68U50SRETr
servier.us
-
Know the signs and symptoms to help raise awareness about acute lymphoblastic leukemia (ALL), a rapidly progressing cancer that starts in the bone marrow and spreads into the blood. Early recognition can make a significant difference in treatment outcomes. Let's work together to support early detection and spread knowledge.
-